CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/07/23
Crispr Therapeutics: Biotech To Watch With Regulatory Approvals Of Exa-Cel On DeckSeeking Alpha • 07/26/23
Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.The Motley Fool • 06/27/23